Dashboard
Manage Tickers

MYNZ MAINZ BIOMED N.V.

Nasdaq mainzbiomed.com


$ 1.45 $ -0.02 (-1.33 %)    

Friday, 31-Oct-2025 15:59:35 EDT
CLICK TO SEE RELEVANT LITIGATION UPDATES
Y-mAbs Therapeutics, Inc. | YMAB | Take Action!
QQQ $ 629.16 $ 3.02 (0.48 %)
DIA $ 475.58 $ 0.66 (0.14 %)
SPY $ 681.80 $ 2.23 (0.33 %)
TLT $ 90.21 $ -0.27 (-0.3 %)
GLD $ 368.20 $ -2.01 (-0.54 %)
$ 1.48
$ 1.48
$ 1.40 x 5,301
$ 1.52 x 98
$ 1.45 - $ 1.51
$ 1.28 - $ 14.39
86,720
na
783,123
$ -0.97
nm
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
No Data found
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

mainz-biomed-announces-topline-results-from-feasibility-study-examining-non-invasive-blood-based-screening-test-for-early-detection-of-pancreatic-cancer-initiated-earlier-in-2025
Mainz Biomed Announces Topline Results Fro...
10/08/2025 13:05:55

Mainz Biomed N.V. (NASDAQ:MYNZ) ("Mainz Biomed" or the "Company"), a molecular genetics diagnostic company spec...

mainz-biomed-launches-coloalert-colorectal-cancer-test-in-switzerland
Mainz Biomed Launches ColoAlert Colorectal...
09/23/2025 12:08:55

Mainz Biomed N.V. (NASDAQ:MYNZ) ("Mainz Biomed" or the "Company"), a molecular genetics diagnostic company spec...

mainz-biomeds-coloalert-receives-mhra-approval-for-colorectal-cancer-screening-in-the-uk
Mainz Biomed's ColoAlert Receives MHRA App...
09/02/2025 12:11:26

Mainz Biomed N.V. (NASDAQ:MYNZ) ("Mainz Biomed" or the "Company"), a molecular genetics diagnostic company spec...

mainz-biomeds-coloalert-receives-swissmedic-approval-paving-way-for-swiss-launch-of-non-invasive-colorectal-cancer-test
Mainz Biomed's ColoAlert Receives Swissmed...
08/13/2025 12:18:46

Mainz Biomed N.V. (NASDAQ:MYNZ) ("Mainz Biomed" or the "Company"), a molecular genetics diagnostic company spec...

mainz-biomed-prices-3m-follow-on-offering-of-222m-units-at-a-price-of-135unit-including-series-a-warrants-immediately-exercisable-for-15-shares
Mainz Biomed Prices $3M Follow-On Offering...
08/04/2025 14:24:34

Mainz Biomed N.V.

Core News & Articles
12 Health Care Stocks Moving In Friday's I...
08/01/2025 17:07:08

mainz-biomed-announces-collaboration-with-care-diagnostica-laborreagenzien-to-support-mainz-in-expanding-coloalert-distribution-in-german-market
Mainz Biomed Announces Collaboration With ...
07/23/2025 12:04:10

Core News & Articles
12 Health Care Stocks Moving In Wednesday'...
07/16/2025 12:08:15

mainz-biomed-reviews-h1-2025-accomplishments-plans-to-complete-eaarly-detect-2-feasibility-study-in-h2-2025
Mainz Biomed Reviews H1 2025 Accomplishmen...
07/15/2025 12:09:30

Mainz Biomed launched eAArly DETECT 2, a US feasibility study to evaluate the Company's next generation colorectal cancer (...

mainz-biomed-to-receive-public-funding-from-nvestitions--und-strukturbank-rheinland-pfalz--for-its-pancreatic-cancer-screening-test
Mainz Biomed To Receive Public Funding Fro...
06/25/2025 12:02:27

mainz-biomed-launches-feasibility-phase-of-pancalert-non-invasive-blood-test-for-early-pancreatic-cancer-detection-following-95-sensitivity-and-98-specificity-results
Mainz Biomed Launches Feasibility Phase Of...
06/10/2025 13:06:00

Mainz Biomed N.V. (NASDAQ:MYNZ) ("Mainz Biomed" or the "Company"), a molecular genetics diagnostic company spec...

reported-earlier-mainz-biomed-prices-4m-offering-of-shares-and-warrants-at-2unit-to-support-cancer-diagnostics-strategy
Reported Earlier, Mainz Biomed Prices $4M ...
05/20/2025 06:47:05

Each unit is being sold at an effective offering price of $2.00 per unit. Each Series A warrant will be immediately exercisable...

Core News & Articles
12 Health Care Stocks Moving In Monday's P...
05/19/2025 12:09:34

why-novavax-shares-are-trading-higher-by-around-17-here-are-20-stocks-moving-premarket
Why Novavax Shares Are Trading Higher By A...
05/19/2025 10:34:22

mainz-biomed-announces-interim-read-out-for-eaarly-detect-2-clinical-study-topline-results-expected-in-q4-2024
Mainz Biomed Announces Interim Read Out Fo...
05/16/2025 12:03:02

"The five novel gene expression (mRNA) biomarkers, which the Company acquired from Sherbrooke University in 2022, have demo...

mainz-biomed-files-for-offer-of-2448980-ordinary-units-and-2488988-pre-funded-units
Mainz Biomed Files For Offer Of 2.,448,980...
05/14/2025 12:55:33

-SEC Filing

mainz-biomed-enters-into-technology-partnership-with-edx-medical-group-to-advance-molecular-diagnostics-technology
Mainz Biomed Enters Into Technology Partne...
04/29/2025 12:06:10

Mainz Biomed N.V. (NASDAQ:MYNZ) ("Mainz Biomed" or the "Company"), a molecular genetics diagnostic company spec...

mainz-biomed-provides-first-quarter-2025-corporate-update-including-path-to-fda-approval-for-its-eaarly-detect-2
Mainz Biomed Provides First Quarter 2025 C...
04/28/2025 12:14:31

Mainz Biomed N.V. (NASDAQ:MYNZ) ("Mainz Biomed" or the "Company"), a molecular genetics diagnostic company spec...

12-health-care-stocks-moving-in-tuesdays-pre-market-session
12 Health Care Stocks Moving In Tuesday's ...
04/08/2025 12:07:41

mainz-biomed-fy24-eps-2236-up-from-6476-yoy-revenue-8939k-down-from-8954k-yoy
Mainz Biomed FY24 EPS ($22.36) Up From ($6...
04/01/2025 12:06:59

CORE & Plaid

CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION